Dalbavancin for Childhood Leukemia

This trial tests a treatment called dalbavancin (an antibiotic) in children and adolescents with specific types of leukemia (a blood cancer). The goal is to determine if dalbavancin can prevent bacterial infections during chemotherapy, a time when the immune system is weak. Researchers aim to learn more about how the body processes the drug and how well patients tolerate it. Children and teens with either acute myeloid leukemia or relapsed lymphoblastic leukemia undergoing chemotherapy might be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to contribute to groundbreaking research.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that dalbavancin is generally safe for children. Past studies found no serious side effects linked to dalbavancin in children, and hearing tests revealed no issues. Some studies found that children have about 30% less dalbavancin in their bodies compared to adults, but it remains safe. Dalbavancin is already used to treat serious skin infections, indicating its safety. However, since this trial is in an early stage, the researchers are primarily focused on understanding its safety and determining the right dose, so they will closely monitor participants.¹²³⁴⁵

Dalbavancin is unique because it's an antibiotic that's being tested for its potential to help treat childhood leukemia, specifically to prevent infections during treatment. Unlike other standard treatments for leukemia that focus solely on chemotherapy, dalbavancin works by targeting bacterial infections, which can be a serious complication for kids undergoing cancer treatment. Researchers are excited about dalbavancin because it is administered once every 28 days, potentially offering a more convenient and less frequent dosing schedule compared to other antibiotics. This can make it easier for young patients and their families to manage during an already challenging time.

Research shows that dalbavancin can help prevent serious infections in children with leukemia. Previous studies have found that dalbavancin is safe and effective for treating complex infections caused by certain bacteria in children. It has also been used to shorten hospital stays, indicating effective infection management. In this trial, participants will receive dalbavancin every 28 days alongside standard fluoroquinolone prophylaxis. Reducing infections is vital for children with leukemia because chemotherapy weakens their immune systems. These findings offer hope that dalbavancin could protect against bacterial infections during cancer treatment.¹⁴⁶⁷⁸